Next-Level Compliance: What Every Board Member Should Know

October 2016

Abstract

This article is geared towards members of Boards of Directors, C-level company leadership, and compliance professionals who recognize the need to continually improve compliance. Why is it important to drive compliance performance to the next level? It is vital, because status quo performance in a rapidly evolving global environment earns a failing mark. If your company is not adapting, if it does not have ethical leaders in the right places setting the right ethical “tone at the top,” the compliance program is not as robust as it should be and the company is likely carrying more compliance-related risk than it should.

Author

Fabiana Lacerca-Allen

Chief Compliance Officer, Cipla, USA

M. Fabiana Lacerca-Allen has over 30 years of experience in legal and compliance roles, working for leading American companies such as Aimmune, Elan, Mylan, Bristol-Myers Squibb Company, Microsoft, Merck, and AT&T. She has counseled and litigated in the field of international business transactions and international environmental law. She has extensive experience in the pharmaceutical industry in leadership roles in charge of legal and compliance teams. She has counseled and represented clients on a broad range of questions, including strategic business initiatives ensuring compliance with laws and regulations, and corporate policy. Ms. Lacerca-Allen has provided legal support and strategic advice on opportunities and trends in law particularly within the government sector, as well as with major and strategic corporate accounts. Fabiana has established policies and oversight on key areas of compliance affecting international markets, and she has been able to positively impact the perception of compliance, creating compliance training programs and relevant standard operating procedures and has been involved in validating and aiding due diligence in the compliance industry, frequently being requested as speaker and participant in forums. She has been recognized in the industry by Hispanic Executive Magazine in 2013, http://hispanicexecutive.com/2013/fabiana-lacerca-allen/; recognized as 2015 Women in Leadership, Inspiring Leaders: http://www.theguardian.com/women-in-leadership/2015/may/12/know-who-you-want-to be-kidnapped-with-and-four-more-tips-for-leaders; served as Chair to the Bay Area Ethics & Compliance Association (BECA); and served as Co Chair for CBI, an Advanstar company serving the Life Sciences industry. Ms. Lacerca-Allen was invited to join the Gioja Research Institute while she was a student researching on environmental law. She was recipient of 1992 UCLA’s tuition waiver based on merit and recognition, and she represented UCLA in the Roscoe Foundation National Essay Contest submitting a paper on Global Warming. About your organization Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide.

Company

Cipla

Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide. Aimmune is on a mission to transform the lives of patients and their families by developing pharmaceutical therapies to prevent, manage, and treat food, GI, and metabolic-related diseases.

As more and more companies have made big compliance mistakes and have been caught by governmental authorities, pundits have been attributing these miscues to company culture. These incidents include the...Read more

David Birk

Managing Director, Black Belt Compliance, LLC, USA

Role of In-House Counsel in Transnational Operations

A fundamental role of in-house legal counsel is to assist the operations teams in identifying, assessing and tailoring their procedures to ensure compliance with applicable requirements and to address the...Read more

Philip Kessack

Vice President and Senior Legal Counsel, AECOM Technology Corporation, USA

Introducing, Implementing and Improving Compliance; Challenges in Cross Boarder Environment and Market Entry Situations

During previous years, the M&A transaction field has been less active. Nevertheless the market is starting to merge again and transactions are appearing on the desks of in-house counsels. In...Read more

Diana Maher

Senior Legal Counsel, Kone Corporation, Finland

UK Economic Crime and Corporate Transparency Act 2023 - Failure to prevent fraud: Storm in a tea cup?

The Failure to Prevent Fraud offence contained within the UK Economic Crime and Corporate Transparency Act 2023 (ECCTA) finally comes into effect on 1 September 2025 following the release of...Read more

Steve Holt

Partner, Grant Thornton UK, UK

Oishi Ghosh

Forensic Investigation Services Manager, Grant Thornton UK, UK

Ollie Haselden

Assistant Manager within the Forensics and Investigations department, Grant Thornton UK, UK

Next-Level Compliance: What Every Board Member Should Know

Abstract

Author

Company

Cipla

Related Papers